title: [Therapeutic efficacy of Ingavirin, a new domestic formulation against influenza A virus (H3N2)].
abstract: Investigation of the therapeutic efficacy of Ingavirin (Valenta Farmacevtica, Russia) against influenza virus A (H3N2) vs. Tamiflu, Remantadin and Arbidol showed that in daily doses of 15 and 20 mg/kg (equal by the efficacy to the human doses of 90 and 120 mg) Ingavirin was effective in protection of the albino mice infected by the virus in a dose of 10 to 15 LD50. The protective efficacy was 38.3-39.2% and the increase of the average lifespan amounted to 4.2-4.4 days. The Ingavirin efficacy was comparable with that of Remantadine, markedly exceeded that of Arbidol and was lower than that of Tamiflu. Investigation of the Ingavirin influence in doses of 15 and 20 mg/kg on the dynamics and level of the influenza virus A/Aichi/2/68 reproduction in the lungs of the infected albino mice weighing 10-12 g revealed that during the whole observation period in the doses tested Ingavirin was effective in inhibition of the influenza virus reproduction. During the whole period of the observation (5 days) Ingavirin was effective in inhibiting the formation of the virus specific hemagglutinin in the target organ.
authors.forename: S Ia
authors.initials: SIa
authors.lastname: Loginova
authors.forename: S V
authors.initials: SV
authors.lastname: Borisevich
authors.forename: V A
authors.initials: VA
authors.lastname: Maksimov
authors.forename: V P
authors.initials: VP
authors.lastname: Bondarev
authors.forename: V E
authors.initials: VE
authors.lastname: Nebol'sin
mesh_terms: D000577:Amides / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002208:Caproates; D003998:Dicarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects*; D008168:Lung / Q000821:virology; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000401:mortality; D053139:Oseltamivir / Q000494:pharmacology / Q000627:therapeutic use; D012299:Rimantadine / Q000494:pharmacology / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects; D013440:Sulfides
chemical_list: D000577:Amides; D000998:Antiviral Agents; D002208:Caproates; D003998:Dicarboxylic Acids; D007093:Imidazoles; D007211:Indoles; D053139:Oseltamivir; D012299:Rimantadine; C539419:pentanedioic acid imidazolyl ethanamide; C086979:umifenovir; D013440:Sulfides